NASDAQ
SPRY

Silverback Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Silverback Therapeutics Inc Stock Price

Vitals

Today's Low:
$7.31
Today's High:
$7.54
Open Price:
$7.54
52W Low:
$3.99
52W High:
$9.65
Prev. Close:
$7.48
Volume:
552468

Company Statistics

Market Cap.:
$679.49 million
Book Value:
2.607
Revenue TTM:
$219000
Operating Margin TTM:
-27549.31%
Gross Profit TTM:
$1.32 million
Profit Margin:
0%
Return on Assets TTM:
-24.74%
Return on Equity TTM:
-38.03%

Company Profile

Silverback Therapeutics Inc had its IPO on 2020-12-04 under the ticker symbol SPRY.

The company operates in the Healthcare sector and Biotechnology industry. Silverback Therapeutics Inc has a staff strength of 29 employees.

Stock update

Shares of Silverback Therapeutics Inc opened at $7.54 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $7.31 - $7.54, and closed at $7.35.

This is a -1.74% slip from the previous day's closing price.

A total volume of 552,468 shares were traded at the close of the day’s session.

In the last one week, shares of Silverback Therapeutics Inc have increased by +3.38%.

Silverback Therapeutics Inc's Key Ratios

Silverback Therapeutics Inc has a market cap of $679.49 million, indicating a price to book ratio of 0 and a price to sales ratio of 329.6943.

In the last 12-months Silverback Therapeutics Inc’s revenue was $219000 with a gross profit of $1.32 million and an EBITDA of $-59987000. The EBITDA ratio measures Silverback Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Silverback Therapeutics Inc’s operating margin was -27549.31% while its return on assets stood at -24.74% with a return of equity of -38.03%.

In Q2, Silverback Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 97.8%.

Silverback Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.56 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Silverback Therapeutics Inc’s profitability.

Silverback Therapeutics Inc stock is trading at a EV to sales ratio of 264.7597 and a EV to EBITDA ratio of -26.5708. Its price to sales ratio in the trailing 12-months stood at 329.6943.

Silverback Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$258.75 million
Total Liabilities
$10.05 million
Operating Cash Flow
$44.97 million
Capital Expenditure
$30000
Dividend Payout Ratio
0%

Silverback Therapeutics Inc ended 2024 with $258.75 million in total assets and $0 in total liabilities. Its intangible assets were valued at $258.75 million while shareholder equity stood at $248.55 million.

Silverback Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $10.05 million in other current liabilities, 9000.00 in common stock, $-109269000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $119.02 million and cash and short-term investments were $252.21 million. The company’s total short-term debt was $233,000 while long-term debt stood at $0.

Silverback Therapeutics Inc’s total current assets stands at $255.03 million while long-term investments were $0 and short-term investments were $133.19 million. Its net receivables were $962000.00 compared to accounts payable of $9.65 million and inventory worth $-962000.00.

In 2024, Silverback Therapeutics Inc's operating cash flow was $44.97 million while its capital expenditure stood at $30000.

Comparatively, Silverback Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$7.35
52-Week High
$9.65
52-Week Low
$3.99
Analyst Target Price
$14

Silverback Therapeutics Inc stock is currently trading at $7.35 per share. It touched a 52-week high of $9.65 and a 52-week low of $9.65. Analysts tracking the stock have a 12-month average target price of $14.

Its 50-day moving average was $6.97 and 200-day moving average was $7.16 The short ratio stood at 16.93 indicating a short percent outstanding of 0%.

Around 3470.6% of the company’s stock are held by insiders while 5898.2% are held by institutions.

Frequently Asked Questions About Silverback Therapeutics Inc

The stock symbol (also called stock or share ticker) of Silverback Therapeutics Inc is SPRY

The IPO of Silverback Therapeutics Inc took place on 2020-12-04

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$1870.8
7.9
+0.42%
$87.61
-4.09
-4.46%
$45.38
0.05
+0.11%
$3.35
-0.06
-1.76%
$10.47
-0.04
-0.43%
$1.98
-0.01
-0.5%
$35
0.94
+2.76%
$92.06
-5.37
-5.51%
$8.58
0.16
+1.9%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.

Address

3525 Del Mar Heights Road, San Diego, CA, United States, 92130